Free Trial
NASDAQ:ENLV

Enlivex Therapeutics Q1 2025 Earnings Report

Enlivex Therapeutics logo
$1.40 +0.05 (+3.33%)
As of 10:41 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Enlivex Therapeutics EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.16
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Enlivex Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Enlivex Therapeutics Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Enlivex Therapeutics' Q1 2025 earnings is scheduled for Friday, August 29, 2025

Conference Call Resources

Enlivex Therapeutics Earnings Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Enlivex Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enlivex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enlivex Therapeutics and other key companies, straight to your email.

About Enlivex Therapeutics

Enlivex Therapeutics (NASDAQ:ENLV), together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

View Enlivex Therapeutics Profile

More Earnings Resources from MarketBeat